Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine

Area of Science:

• Oncology
• Proteomics
• Molecular Biology

Background:

• Cancer is characterized by deregulated intracellular signaling due to genetic alterations.
• Identifying key genetic changes and targeting active signaling molecules are crucial for cancer therapy.
• Therapeutic efficacy varies, necessitating precise molecular profiling for personalized treatment.

Purpose of the Study:

• To review and discuss the application of Reverse-Phase Protein Array (RPPA) technology in cancer research.
• To highlight RPPA's advantages in profiling signaling proteins for therapy optimization.
• To discuss RPPA's role in basic, preclinical, and clinical research, including its integration into clinical trials.

Main Methods:

• Reverse-phase protein array (RPPA) technology, an antibody-based quantitative proteomic method.
• Profiling of protein expression and modification, particularly for low-abundance signaling proteins.
• Application in clinical proteomics due to high sensitivity and accurate quantification with limited clinical samples.

Main Results:

• RPPA is highly suitable for profiling signaling proteins, even those present in low abundance.
• The technology provides sensitive and accurate quantification, making it advantageous for clinical proteomics with limited samples.
• RPPA is increasingly incorporated into clinical trials for molecular-targeted therapeutics.

Conclusions:

• RPPA is a valuable tool for molecularly characterizing cancers and optimizing targeted therapies.
• Its sensitivity and quantitative nature make it ideal for clinical proteomics and personalized medicine.
• The RPPA Global Workshop aims to foster knowledge exchange and advance the technology's application worldwide.